TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06314685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: As a experimental vaccine for 6 months to 5 years old.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: As a experimental vaccine for 6 months to 5 years old.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: As a experimental vaccine for 6 months to 5 years old.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A and C Meningococcal Polysaccharide Vaccine
Description: As a control vaccine for ages 6-11 months and 12-23 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A and C Meningococcal Polysaccharide Vaccine
Description: As a control vaccine for ages 6-11 months and 12-23 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Vaccine
Description: As a control vaccine for ages 2-5 years.
Study: NCT05769933

Intervention type: DEVICE
Intervention: Simultaneous EEG-fMRI at 7 Tesla
Description: Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
Study: NCT05112484

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic testing
Description: One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic testing
Description: One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parameters for routine use of DMDs
Description: For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs).
Study: NCT05255692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: invasive urodynamic evaluation
Description: Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging during bladder filling
Description: Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
Study: NCT06549465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: In-111 rosopatamab tetraxetan
Description: A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
Study: NCT05112484

Intervention type: DIAGNOSTIC_TEST
Intervention: Parameters for routine use of DMDs
Description: For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs).

Intervention type: DIAGNOSTIC_TEST
Intervention: Parameters for routine use of DMDs
Description: For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs).

Intervention type: DIAGNOSTIC_TEST
Intervention: Parameters for routine use of DMDs
Description: For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs).

Intervention type: OTHER
Intervention: Side effects of orally used DMDs
Description: For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed.

Intervention type: OTHER
Intervention: Side effects of orally used DMDs
Description: For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed.

Intervention type: OTHER
Intervention: Side effects of orally used DMDs
Description: For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed.

Intervention type: OTHER
Intervention: Side effects of orally used DMDs
Description: For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed.
Study: NCT06186804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
Study: NCT06145893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 60mg bid p.o;
Study: NCT04958798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Centered MOUD Implementation Intervention
Description: Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
Study: NCT06145893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 45mg bid p.o;
Study: NCT01322477

Intervention type: OTHER
Intervention: F18-FDG PET/CT
Study: NCT05180591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Study: NCT06057116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
Study: NCT05769933

Intervention type: DEVICE
Intervention: Simultaneous EEG-fMRI at 7 Tesla
Description: Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Simultaneous EEG-fMRI at 7 Tesla
Description: Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Structural MRI at 7 Tesla
Description: Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Structural MRI at 7 Tesla
Description: Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Structural MRI at 7 Tesla
Description: Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Structural MRI at 7 Tesla
Description: Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.

Intervention type: DEVICE
Intervention: Structural MRI at 7 Tesla
Description: Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
Study: NCT05197218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
Study: NCT05530148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Martial Arts Training Group
Description: Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexing, Toning and Balance
Description: Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
Study: NCT06549465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 45 KBq/kg Ac-225 rosopatamab tetraxetan
Description: 45 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 55 KBq/kg Ac-225 rosopatamab tetraxetan
Description: 55 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
Study: NCT06145893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to Hemay005 tables bid p.o
Study: NCT05293171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg BL-8040 + BL-8040-matching placebo
Description: Administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg/kg BL-8040
Description: Administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BL-8040-matching placebo
Description: Administered subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Moxifloxacin (1x400 mg tablet)
Description: Administered orally
Study: NCT05835713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
Study: NCT05554718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Smartphone App
Description: The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Smartphone App
Description: The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-guided App Use
Description: In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
Study: NCT06277583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban care farming
Description: An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Urban care farming
Description: An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
Study: NCT06372197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
Study: NCT05625633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: 0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
Study: NCT03869671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP uptake/adherence intervention
Description: The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Harm reduction standard of care
Description: Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
Study: NCT04976296

Intervention type: DIAGNOSTIC_TEST
Intervention: MRD detection
Description: The Geneplus OncoMRD lung assay is used to detect the MRD status.
Study: NCT05304819

Intervention type: DEVICE
Intervention: AchilloCordPLUS™ System Implant
Description: AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
Study: NCT06549465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 55 KBq/kg Ac-225 rosopatamab tetraxetan
Description: 55 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 KBq/kg Ac-225 rosopatamab tetraxetan
Description: 60 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 KBq/kg Ac-225 rosopatamab tetraxetan
Description: 60 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
Study: NCT06074237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive resident education
Description: Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) encounter
Description: After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter.
Study: NCT04997382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
Description: Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone or Chemotherapy with or without Bevacizumab
Description: Bevacizumab, 15mg/kg，every 21 day
Study: NCT05207111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin Inhalation Solution
Description: Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
Study: NCT05067530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study: NCT05796388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Both groups will receive standard of care linaclotide 290 mcg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: Both groups will receive standard of care linaclotide 290 mcg.
Study: NCT04143581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg/die for 28 days
Study: NCT05295264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise program
Description: Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy.
Study: NCT05067530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy
Study: NCT05367518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)
Description: Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)
Description: Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study: NCT06109337

Intervention type: DIAGNOSTIC_TEST
Intervention: drow blood
Description: Participants will be taken peripheral blood about 5 ml
Study: NCT04463446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of the CHD app
Description: Use of the CHD app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led intervention
Description: Teaching session with clinic nurse